AngioDynamics, Inc. — Form 10-Q Summary
Reporting period: Second quarter and first six months of fiscal 2014, ended November 30, 2013. The filing is unaudited. AngioDynamics develops and sells medical devices used in vascular access, peripheral vascular disease, oncology and surgery.
Financial performance
| Metric | Three months ended Nov. 30, 2013 | Prior-year quarter | Six months ended Nov. 30, 2013 | Prior-year six months |
|---|---|---|---|---|
| Net sales | $88.6 million | $87.0 million | $172.2 million | $170.4 million |
| Gross profit / margin | $44.9 million / 50.7% | $44.1 million / 50.7% | $87.4 million / 50.8% | $83.5 million / 49.0% |
| Operating income / margin | $1.6 million / 1.8% | $5.1 million / 5.9% | $2.9 million / 1.7% | $5.8 million / 3.4% |
| Net income (loss) | $(0.1) million | $2.0 million | $(0.5) million | $1.2 million |
| Diluted earnings (loss) per share | $(0.00) | $0.06 | $(0.01) | $0.04 |
| Operating cash flow | Not presented by quarter | $15.8 million | $5.5 million |
Quarterly revenue increased 2%; first-half revenue increased 1%. Quarterly gross margin was unchanged, while the first-half margin improved, partly because the prior-year period included $3.4 million of acquired Navilyst inventory step-up amortization. Operating profitability declined in both comparisons as sales and marketing costs, contingent-consideration remeasurement and the new medical device excise tax weighed on results.
For the quarter, Peripheral Vascular sales rose 7% to $48.9 million; Vascular Access fell to $25.6 million; and Oncology/Surgery rose 5% to $12.6 million. U.S. sales increased 4% to $69.5 million, international sales rose 1% to $17.5 million, and supply-agreement sales declined 35% to $1.6 million.
Financial position, cash flow and debt
- At November 30, cash, cash equivalents and marketable securities totaled $17.0 million, down from $24.0 million at May 31. Current assets were $141.6 million and current liabilities $69.1 million.
- Total debt was approximately $140.2 million: $98.8 million outstanding on the term loan and $41.4 million on the revolver. The company reported $72.4 million of acquisition-related contingent consideration fair value, including $12.2 million classified as current.
- First-half operating cash flow of $15.8 million was mainly supported by non-cash expenses, partly offset by increased inventory and other working-capital movements. Investing activities used $11.2 million, including capital spending and the Clinical Devices acquisition; financing activities used $11.2 million, including debt repayment and contingent-consideration payments. Cash declined $6.6 million.
- Management said cash and investments, operating cash generation and the $100 million revolving facility should meet anticipated capital needs for at least 12 months. Significant cash acquisitions could require external financing.
Material changes, outlook and risks
- Sales gains came mainly from EVLT procedure kits, AngioVac and microwave products; declines in PICCs, RFA, Habib devices and supply-agreement products partly offset growth. Sales and marketing expense rose 13% in the quarter as the company expanded sales forces. The $1.0 million quarterly medical device excise tax was a new operating expense.
- On September 19, 2013, the company refinanced its prior credit agreement with five-year, senior secured term and revolving facilities, each with a $100 million commitment. The facilities have leverage and fixed-charge covenants; AngioDynamics reported compliance at November 30. Substantially all company and guarantor assets secure the debt.
- A December 5, 2013 operational-excellence program, announced after quarter-end, targets $15–$18 million in savings over three years through product rationalization, manufacturing and supply-chain changes, ERP implementation, and consolidation of New York facilities. The plan anticipates reducing the New York workforce by approximately 80–100 positions. These are targets, not guaranteed results.
- Acquisitions added contingent-payment exposure. The company estimated approximately $91.7 million of undiscounted future contingent consideration, payable only if specified sales, operating or development milestones are achieved. Fair-value estimates rely on significant unobservable assumptions and can change.
- Regulatory risk remains: the filing describes a prior FDA Warning Letter and several Form 483 observations concerning quality systems at manufacturing facilities. The company reported corrective efforts and continued FDA engagement, but warned that unresolved matters could lead to further regulatory action, including restrictions, fines, recalls or facility disruption.
- Material legal matters include AngioDynamics’ efforts to recover from biolitec-related entities and a stayed patent-infringement action brought by C.R. Bard. The company stated it could not determine whether a loss in the Bard matter was probable or reasonably estimable and had recorded no expense for it. Cardinal Health arbitration was dismissed with prejudice; the former-employee case was settled with no expected financial impact.
- No specific revenue or earnings guidance was provided in the filing. Forward-looking statements are subject to product-development, regulatory, clinical-trial, litigation, market-acceptance, pricing, competition, foreign-exchange and acquisition-integration risks.
Most important facts for investors to verify
- Whether modest revenue growth can translate into improved operating margins given higher selling costs, excise tax and acquisition-related expenses.
- Progress and realized savings from the three-year operational-excellence program, including restructuring costs and workforce reductions.
- Debt levels, covenant headroom, interest-rate exposure and the company’s ability to preserve liquidity while meeting contingent acquisition payments.
- Resolution of FDA quality-system matters and the status and potential financial effects of the Bard and biolitec litigation.
- Whether acquisition-related sales and milestones support the contingent-consideration valuations, and whether goodwill or intangible assets remain recoverable.